Moderna's Pipeline Meets Its Balance Sheet: Canada Approves Both Flu Shots as Q3 Revenue Climbs 29%

Moderna closed out a busy week with a pair of regulatory wins in Canada, fresh clinical momentum on two fronts and a quarterly report that gave investors something the company has rarely offered lately: evidence that the core business is expanding on its own.

Health Canada has cleared both mFLUSIVA, a standalone seasonal influenza vaccine, and mCOFLU, a combined flu/COVID-19 shot. According to the company, Canada is the first country to approve both products. The dual green light matters because it hands Moderna a commercial foothold beyond its COVID-19 franchise rather than a single-product extension of it.

A regulatory first, with commercial proof still pending

For all the symbolic weight of being first to market, the investment case now hinges on execution. The approvals only gain value if the products find demand and start contributing revenue. That is the yardstick investors should apply — the expanded opportunity is real, but how much it changes the company economically depends on how Moderna converts it.

The same logic applies to the research updates Moderna released on Wednesday. A World Health Organization technical advisory group recommended the company's experimental Bundibugyo Ebola vaccine for inclusion in an efficacy trial, based on Phase 1 clinical results. The recommendation is a constructive step, though its significance will be defined by the trials that follow. A successful efficacy readout would count for far more than the endorsement itself.

Separately, Moderna said first clinical data from the Phase 1/2 program for mRNA-2808, a multiple myeloma candidate, has been selected for an oral presentation at the American Society of Hematology's 2026 annual meeting. That selection is worth watching precisely because it promises data specific enough to support a real assessment of the program.

The quarter behind the pipeline

Friday's results supply the financial backdrop. Moderna reported third-quarter 2026 revenue of $1.31 billion, up 29%, with GAAP net income of $162 million. Reuters attributed the quarter's strength to robust international demand for COVID-19 vaccines and payments tied to partnerships.

The company also raised its full-year 2026 revenue growth guidance to 15%–25%, up from a prior expectation of no more than 10%. That upgrade rests on the same international COVID-19 demand and partnership deliveries, and it gives the broader product story a firmer financial floor.

Investors rewarded the combination: the stock added 5.7% on Friday.

A patent truce and a date to circle

Legal risk also eased. Reuters reported on October 28 that Moderna settled its U.S. and European patent disputes with GSK over its COVID-19 and RSV vaccines. The agreement provides for mutual patent licenses covering infectious diseases and requires no payments — a clean resolution that complements the operating news.

Next up is the company's announced analyst day on November 12, where management is expected to address how it plans to knit the existing business together with the newer applications.

The distinction worth keeping in view is one of development stage. Revenue and profit describe the present. The Canadian flu approvals represent regulatory progress. The melanoma data — in which the combination reduced the risk of melanoma recurrence or death by 42% versus KEYTRUDA alone — represent a clinical signal, and one that speaks to the shared development program's potential provided further progress opens a path to commercial use.

That 42% figure is the heart of the research story: a clinical advantage over KEYTRUDA monotherapy. What it does not yet do is settle the economic question.

Breadth is the thread running through all of it — a vaccine franchise widening beyond COVID-19, a cancer program advancing, litigation closed out and guidance moving higher. Whether that breadth coheres into a durable business depends on sustained demand and on how far each program actually travels. On that measure, the week's news offers more to track than to bank.